Logo image of SERA

SERA PROGNOSTICS INC-A (SERA) Stock Fundamental Analysis

NASDAQ:SERA - Nasdaq - US81749D1072 - Common Stock - Currency: USD

2.605  -1.48 (-36.31%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SERA. SERA was compared to 555 industry peers in the Biotechnology industry. The financial health of SERA is average, but there are quite some concerns on its profitability. SERA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SERA had negative earnings in the past year.
In the past year SERA has reported a negative cash flow from operations.
In the past 5 years SERA always reported negative net income.
In the past 5 years SERA always reported negative operating cash flow.
SERA Yearly Net Income VS EBIT VS OCF VS FCFSERA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of SERA (-27.96%) is better than 69.37% of its industry peers.
With a decent Return On Equity value of -34.73%, SERA is doing good in the industry, outperforming 74.05% of the companies in the same industry.
Industry RankSector Rank
ROA -27.96%
ROE -34.73%
ROIC N/A
ROA(3y)-40.37%
ROA(5y)-55.81%
ROE(3y)-54.95%
ROE(5y)-196.82%
ROIC(3y)N/A
ROIC(5y)N/A
SERA Yearly ROA, ROE, ROICSERA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

SERA's Gross Margin of 8.70% is fine compared to the rest of the industry. SERA outperforms 72.79% of its industry peers.
The Profit Margin and Operating Margin are not available for SERA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 8.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SERA Yearly Profit, Operating, Gross MarginsSERA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

SERA does not have a ROIC to compare to the WACC, probably because it is not profitable.
SERA has more shares outstanding than it did 1 year ago.
SERA has more shares outstanding than it did 5 years ago.
SERA has a better debt/assets ratio than last year.
SERA Yearly Shares OutstandingSERA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
SERA Yearly Total Debt VS Total AssetsSERA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -0.18, we must say that SERA is in the distress zone and has some risk of bankruptcy.
SERA has a better Altman-Z score (-0.18) than 61.62% of its industry peers.
SERA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.18
ROIC/WACCN/A
WACC8.92%
SERA Yearly LT Debt VS Equity VS FCFSERA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 2.04 indicates that SERA has no problem at all paying its short term obligations.
SERA has a worse Current ratio (2.04) than 75.14% of its industry peers.
A Quick Ratio of 2.04 indicates that SERA has no problem at all paying its short term obligations.
With a Quick ratio value of 2.04, SERA is not doing good in the industry: 73.15% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.04
Quick Ratio 2.04
SERA Yearly Current Assets VS Current LiabilitesSERA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

SERA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.15%, which is quite good.
Looking at the last year, SERA shows a very negative growth in Revenue. The Revenue has decreased by -42.79% in the last year.
SERA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.00% yearly.
EPS 1Y (TTM)12.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)-42.79%
Revenue growth 3Y-1.27%
Revenue growth 5Y14%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 6.52% on average over the next years.
Based on estimates for the next years, SERA will show a very strong growth in Revenue. The Revenue will grow by 206.18% on average per year.
EPS Next Y8.3%
EPS Next 2Y1.56%
EPS Next 3Y2.04%
EPS Next 5Y6.52%
Revenue Next Year236.36%
Revenue Next 2Y326.4%
Revenue Next 3Y293.45%
Revenue Next 5Y206.18%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SERA Yearly Revenue VS EstimatesSERA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
SERA Yearly EPS VS EstimatesSERA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SERA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SERA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SERA Price Earnings VS Forward Price EarningsSERA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SERA Per share dataSERA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.56%
EPS Next 3Y2.04%

More info and screens

0

5. Dividend

5.1 Amount

SERA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SERA PROGNOSTICS INC-A

NASDAQ:SERA (6/30/2025, 2:52:05 PM)

2.605

-1.48 (-36.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)N/A N/A
Inst Owners69.94%
Inst Owner Change11.87%
Ins Owners2.81%
Ins Owner Change9.57%
Market Cap98.13M
Analysts85
Price TargetN/A
Short Float %3.09%
Short Ratio4.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.31%
Min EPS beat(2)-2.12%
Max EPS beat(2)14.75%
EPS beat(4)2
Avg EPS beat(4)3.3%
Min EPS beat(4)-6.95%
Max EPS beat(4)14.75%
EPS beat(8)6
Avg EPS beat(8)8.45%
EPS beat(12)10
Avg EPS beat(12)12.34%
EPS beat(16)10
Avg EPS beat(16)-6.08%
Revenue beat(2)1
Avg Revenue beat(2)1.72%
Min Revenue beat(2)-53.43%
Max Revenue beat(2)56.86%
Revenue beat(4)1
Avg Revenue beat(4)-33.86%
Min Revenue beat(4)-72.32%
Max Revenue beat(4)56.86%
Revenue beat(8)2
Avg Revenue beat(8)-38.58%
Revenue beat(12)3
Avg Revenue beat(12)-30.55%
Revenue beat(16)4
Avg Revenue beat(16)-28.86%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.26%
EPS NY rev (1m)0%
EPS NY rev (3m)6.32%
Revenue NQ rev (1m)30%
Revenue NQ rev (3m)-18.75%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-89.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 853.31
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.04
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0
BVpS2.52
TBVpS2.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.96%
ROE -34.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 8.7%
FCFM N/A
ROA(3y)-40.37%
ROA(5y)-55.81%
ROE(3y)-54.95%
ROE(5y)-196.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.43%
Cap/Sales 339.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.04
Quick Ratio 2.04
Altman-Z -0.18
F-Score3
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)83.64%
Cap/Depr(5y)92.91%
Cap/Sales(3y)587.88%
Cap/Sales(5y)777.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y8.3%
EPS Next 2Y1.56%
EPS Next 3Y2.04%
EPS Next 5Y6.52%
Revenue 1Y (TTM)-42.79%
Revenue growth 3Y-1.27%
Revenue growth 5Y14%
Sales Q2Q%N/A
Revenue Next Year236.36%
Revenue Next 2Y326.4%
Revenue Next 3Y293.45%
Revenue Next 5Y206.18%
EBIT growth 1Y2.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.33%
OCF growth 3YN/A
OCF growth 5YN/A